Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pfizer CFO to depart; GSK wins approval for UTI drug

Summary by endpoints.news
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept resubmission, Verastem pancreatic update, Legend offering, COUR Series B and two program cuts, cAMPfield $180M debut and LabGenius-LG Chem AI pact.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

endpoints.newsendpoints.news

Pfizer CFO to depart; GSK wins approval for UTI drug

Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept resubmission, Verastem pancreatic update, Legend offering, COUR Series B and two program cuts, cAMPfield $180M debut and LabGenius-LG Chem AI pact.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news on Thursday, June 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

CFO icon

CFO

UTI icon

UTI

FDA icon

FDA

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal